Suggestions
Felipe de Sousa e Melo
Director | Large Molecule Modalities | Induced Proximity Platform
Felipe de Sousa e Melo is a senior scientist and researcher currently working as the Director of the Induced Proximity Platform at Amgen.12 He is based in San Mateo, California, United States.12
Professional Background
Education and Early Career: Felipe holds a PhD in Oncology and Cancer Biology from the University of Amsterdam, which he completed between 2008 and 2013.12 Prior to his doctoral studies, he obtained a Master's degree in Cancer and Immunology (2006-2008) and a Bachelor of Science in Biochemistry and Molecular Biology (2002-2005).2
Career Progression: Felipe's career has been marked by steady advancement in the field of cancer research:
- He started as a PhD student at the Academic Medical Center in Amsterdam (2008-2012).1
- Following his PhD, he worked as a Postdoctoral Researcher at the same institution (2012-2013).1
- He then moved to Genentech, where he served as a Postdoctoral Fellow (2014-2017) and later as a Senior Scientist (2018-present).1
- Currently, he holds the position of Director - Induced Proximity Platform at Amgen.23
Research Focus and Expertise
Felipe leads a multidisciplinary research group focused on developing novel approaches in cancer research.1 His areas of expertise include:
- Cancer Biology
- Cancer Therapy
- Cancer Diagnostics
- Cancer Animal Models
- Data Mining
- Oncology4
His work has involved leveraging genome engineering technology and tumor modeling to investigate the role of cancer stem cells in tumor growth and metastasis.1
Achievements and Recognition
Throughout his career, Felipe has received several awards for his research contributions:
- STAT Wunderkind 20191
- Multiple AMC Publication Awards (2011, 2012, 2013)1
- PhD Thesis Award from the Academic Medical Center Amsterdam (2013)1
Felipe de Sousa e Melo's career trajectory demonstrates his significant contributions to cancer research and his leadership in developing innovative approaches to understanding and treating cancer.
Highlights
Exciting study published in Nature today, using engineering platforms and organoids to delve into cancer progression with remarkable fidelity.
Congratulations to Matthias Lutolf and the team! Dive into the details, including insights in the associated News and Views, written with my colleague Nicolo Riggi.
https://lnkd.in/gAmY9FeC
https://lnkd.in/gEuQyiyV
After 10 phenomenal years at Genentech, I’m excited to embark on a new chapter as the director of large molecule modalities within the induced proximity platform at Amgen research. Thrilled to contribute to unlocking the full potential of multi-specific antibodies across Amgen’s diverse therapeutic areas. Grateful for the incredible journey at Genentech, and looking forward to new challenges and opportunities ahead!
